There has been an increasing standard of living in the Middle East and Africa due to higher national income. This has contributed to a higher incidence of heart disease - high blood pressure, high cholesterol and high blood sugar.
In fact, the Middle East/Africa region is one of the higher areas for heart disease which has prompted more individuals being admitted to the hospital. This has caused an uptick in the demand for diagnostic testing devices and medical devices.
Scope
The Middle East, Africa market for in vitro diagnostics is provided in U.S. dollars for the years 2021 - 2026.
The report covers six segments of the IVD market in the Middle East:
Clinical Chemistry
Immunoassay
Microbiology
Point of Care (POC)
Histology - traditional stains
Other (includes nucleic acid assays, blood bank ABO, sequencing, prenatal tests and other areas not covered specifically in the above segments)
This report provides an overview of developments in the in vitro diagnostics industry in the Middle East and Africa with focus on the following countries
Egypt
Iran
Iraq
Israel
Jordan
Saudi Arabia
South Africa
Turkey
United Arab Emirates (UAE)
Other Mideast (Bahrain, Cyprus, Gaza Strip, Kuwait, Lebanon, Oman, Qatar, Syria, West Bank, Yemen)
Other Africa (Algeria, Congo, Sudan, Libya, Chad, Niger, Angola, Mali, Ethiopia, etc.)
Key Topics Covered:
Chapter 1: Executive Summary
Overview
Scope and Methodology
Size and Growth of the Market
Chapter 2: Middle East and Africa: Regional Overview
Overview
Regional Market Overview
Population
Major Diseases Affecting the Middle Eastern/African Population
Cardiovascular Diseases
Cancer
Diabetes
Middle Eastern Respiratory Syndrome (MERS)
SARS-CoV-2 (COVID-19)
Chapter 3: Egypt IVD Market
Overview
Market Summary
Market Strengths and Weaknesses (Drivers and Inhibitors)
COVID-19 Pandemic Situation
Market Participant Activity
Chapter 4: Iran IVD Market
Overview
Market Summary
Market Strengths and Weaknesses (Drivers and Inhibitors)
COVID-19 Pandemic Situation
Chapter 5: Iraq IVD Market
Overview
Market Summary
Market Strengths and Weaknesses (Drivers and Inhibitors)
COVID-19 Pandemic Situation
Market Participant Activity
Chapter 6: Israel IVD Market
Overview
Market Summary
Market Strengths and Weaknesses (Drivers and Inhibitors)
COVID-19 Pandemic Situation
Market Participant Activity
Chapter 7: Jordan IVD Market
Overview
Market Summary
Market Strengths and Weaknesses (Drivers and Inhibitors)
COVID-19 Pandemic Situation
Chapter 8: Saudi Arabia IVD Market
Overview
Market Summary
Market Strengths and Weaknesses (Drivers and Inhibitors)
COVID-19 Pandemic Situation
Market Participant Activity
Chapter 9: South Africa IVD Market
Overview
Market Summary
Market Strengths and Weaknesses (Drivers and Inhibitors)
Ebola Outbreaks
COVID-19 Pandemic Situation
Market Participant Activity
Chapter 10: Turkey IVD Market
Overview
Market Summary
Market Strengths and Weaknesses (Drivers and Inhibitors)
COVID-19 Pandemic Situation
Market Participant Activity
Chapter 11: United Arab Emirates (UAE) IVD Market
Overview
Market Summary
Market Strengths and Weaknesses (Drivers and Inhibitors)
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company"). This action, captioned Hope v. agilon health, inc., et...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...